Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
5 Top-Ranked Cheap Dividend Growth Stocks
by Sweta Killa
While there are several dividend stocks that could provide capital appreciation, honing in on stocks with a history of dividend growth leads to a healthy portfolio with a greater scope of capital appreciation.
What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?
by Zacks Equity Research
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
Why Earnings Season Could Be Great for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
TMO or ABMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TMO vs. ABMD: Which Stock Is the Better Value Option?
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?
by Zacks Equity Research
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Can Five Elements Drive Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) seems in sync with its strategy to expedite growth and operational excellence.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Solid Consumables Drive Illumina's (ILMN) Q1 Earnings?
by Zacks Equity Research
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Top Ranked Momentum Stocks to Buy for April 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 16th
Can Medical Devices Strength Drive Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.
Will Abbott's (ABT) Steady Overall Growth Aid Q1 Earnings?
by Zacks Equity Research
At the end of 2018, Abbott (ABT) posts some encouraging data, buoying investors' optimism on its Diabetes Care segment.
The Zacks Analyst Blog Highlights: Mastercard, Honeywell, Thermo Fisher, Cigna and Norfolk Southern
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Honeywell, Thermo Fisher, Cigna and Norfolk Southern
Zacks.com featured expert Kevin Matras highlights: SS&C Technologies, Thermo Fisher Scientific, Columbia Sportswear, Heidrick & Struggles International and Anthem
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: SS &C Technologies, Thermo Fisher Scientific, Columbia Sportswear, Heidrick & Struggles International and Anthem
Thermo Fisher (TMO) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Top-Ranked Dividend Stocks That Ensure Solid Growth
by Sweta Killa
Given a dovish Fed and bouts of market volatility, investors are in search of steady income with some aspect of growth.
5 Top-Ranked Dividend Stocks That Ensure Solid Growth
by Sweta Killa
Given a dovish Fed and bouts of market volatility, investors are in search of steady income with some aspect of growth.
Top Analyst Reports for Mastercard, Honeywell & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Honeywell (HON) and Thermo Fisher (TMO).
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip
by Zacks Equity Research
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.
The Zacks Analyst Blog Highlights: Amazon, Berkshire Hathaway, Thermo Fisher, Square and Public Service
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Berkshire Hathaway, Thermo Fisher, Square and Public Service
Semtech (SMTC) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Semtech's (SMTC) differentiated growth drivers and diversification strategy are likely to drive fiscal fourth-quarter results. However, exposure to seasonality and competition remain concerns.
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
Roper (ROP) Sells Scientific Imaging Businesses to Teledyne
by Zacks Equity Research
The divestment of Roper's (ROP) Scientific Imaging businesses is in sync with its inorganic growth strategy.
The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer